Skip to main content
. 2022 Mar 15;42(4):319–331. doi: 10.1007/s40261-022-01120-2
Aclidinium and aclidinium/formoterol users showed similar characteristics to those of other LAMA users.
Among the study medication groups, aclidinium and aclidinium/formoterol users, and LAMA users in general, were older and had a high frequency of severe COPD, chronic comorbidities and use of COPD comedications.
Off-label prescribing of aclidinium and aclidinium/formoterol is low.